Welcome to Markets Desk, here's what's moving.
Biogen and Eisai are out with real-world data on LEQEMBI, their Alzheimer's treatment, and the numbers are meaningful. The LEADER study, presented at AAIC two thousand twenty six, showed nearly eighty-three percent of early Alzheimer's patients either remained stable or showed improvement over an average of seventeen months. That kind of real-world durability matters enormously for commercial uptake and reimbursement conversations.
Shifting to biotech financing, Inhibikase Therapeutics saw its shares climb five percent after the company raised fifty million dollars through a direct share sale to RA Capital Management. The proceeds target its pulmonary arterial hypertension program, and the fact that a credible institutional name like RA Capital stepped in through an at-the-market facility signals genuine conviction in the pipeline at this stage.
And on the macro side, a story worth watching for Florida's fiscal picture. The state's ambitious tax cut plan rests heavily on continued population inflows, but recent data shows migration into Florida has fallen roughly ninety percent from its pandemic-era peak. When a revenue model is built on demographic momentum that has largely evaporated, the budget math deserves serious scrutiny from bond investors watching state credit.
That's the tape. Markets Desk, signing off the floor.
